Compare Regeneron Pharmaceuticals Inc (REGN) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while TotalEnergies SE trades at $84.5 (market cap $184.64B). The key difference: TotalEnergies SE is far larger — about 2.6× Regeneron Pharmaceuticals Inc's market cap, and TotalEnergies SE pays the higher dividend (5.05%). Which is the better fit depends on your goals.
| REGN | TTE | |
|---|---|---|
Market Cap | $70.79B | $184.64B |
Sector | Health | Energy |
52-Week High | $812.27 | $93.60 |
52-Week Low | $545.46 | $57.39 |
Enterprise Value | $64.74B | $218.78B |
Dividend Yield | 0.56% | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
TotalEnergies (TTE) trades at $83.53, up 2.63% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.99 and P/S of 0.96, with strong profitability margins. Recent Q1 2026 earnings beat expectations at $2.45 EPS, while analysts maintain a consensus Buy rating with $100 price target representing 20% upside potential.
TTE presents compelling value with conservative valuation and steady dividend payments, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Key risks include ongoing Middle East exposure and energy price volatility. The upcoming Q2 earnings report on July 23rd will be crucial for confirming the positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
